Henry Schein Exceeds Q4 Earnings Estimates, Guides Steady 2026 Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy HSIC?
Source: Newsfilter
- Earnings Beat: Henry Schein's Q4 earnings and sales surpassed market expectations, resulting in nearly a 10% share price increase on Tuesday, indicating strong performance and market confidence in the healthcare products sector.
- Sales Growth Drivers: The reported sales growth reflects ongoing demand in the healthcare industry, which is expected to lay a solid foundation for future financial performance and enhance investor confidence in the company's long-term growth potential.
- 2026 Growth Guidance: The company maintains steady growth guidance for 2026, signaling optimism about future market conditions and aiming for sustainable development through continuous innovation and market expansion.
- Increased Shareholder Returns: With the significant rise in share price, the company may consider enhancing shareholder return measures, further attracting investors and increasing market attention on its stock.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HSIC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HSIC
Wall Street analysts forecast HSIC stock price to fall
10 Analyst Rating
5 Buy
3 Hold
2 Sell
Moderate Buy
Current: 80.210
Low
58.00
Averages
76.78
High
90.00
Current: 80.210
Low
58.00
Averages
76.78
High
90.00
About HSIC
Henry Schein, Inc. is a solutions company for healthcare professionals. Its segments consist of Global Distribution and Value-Added services, Global Specialty Services, and Global Technology. Global Distribution and Value-Added Services include the distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting and other services. This segment also markets and sells under its own brand, a portfolio of consumable merchandise. The Global Specialty Products includes the manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other healthcare-related products and services. Global Technology includes the development and distribution of practice management software, e-services, and other products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Henry Schein Insider Plans to Sell 3.61 Million Shares of Common Stock via Form 144
Stock Sale Announcement: Stanley M. Bergman intends to sell 43,812 shares of Henry Schein (HSIC.US) common stock on March 2, with a total market value of approximately $3.61 million.
Reduction in Shareholding: Stanley M. Bergman has reduced his shareholding in Henry Schein by 53,831 shares since February 26, 2026, with a total value of approximately $4.36 million.
See More
Henry Schein Reports Strong Q4 Earnings Exceeding Expectations
- Earnings Growth: Henry Schein reported adjusted Q4 earnings of $1.34 per share, a 12.6% increase from $1.19 a year ago, surpassing the consensus estimate of $1.30, indicating sustained profitability improvements.
- Sales Surge: The company achieved Q4 sales of $3.44 billion, exceeding the expected $3.35 billion, reflecting strong performance across global equipment, specialty products, and technology sectors, driving the highest sales growth in 15 quarters.
- Future Guidance: Henry Schein anticipates adjusted earnings for fiscal 2026 to range between $5.23 and $5.37 per share, slightly below the consensus of $5.30, while projecting sales of $13.58 billion to $13.84 billion, indicating a year-over-year growth of 3% to 5%, showcasing confidence in future performance.
- Stock Fluctuation: Despite strong earnings, Henry Schein's stock fell 1.7% to $81.90 on Wednesday, reflecting market caution regarding the company's future performance, which may impact investor sentiment.
See More
US Stocks Rebound Led by Software and Chipmakers
- Market Rebound: The S&P 500 Index rose by 0.77%, the Dow Jones Industrial Average increased by 0.76%, and the Nasdaq 100 Index climbed by 1.09%, indicating a recovery after Monday's sharp declines, reflecting investor optimism regarding economic data.
- Software and Chip Stocks Surge: Following AI startup Anthropic PBC's emphasis on partnerships, software and chip manufacturers saw significant stock price increases, indicating growing market confidence in the integration of AI technologies, which could enhance their competitive positioning.
- Consumer Confidence Boost: The US February consumer confidence index rose by 2.2 to 91.2, surpassing expectations of 87.1, suggesting increased consumer optimism about the economic outlook, which may lead to higher consumer spending and positively impact economic growth.
- Interest Rates and Economic Data Focus: The market is discounting only a 2% chance of a rate cut at the Fed's March 17-18 meeting, indicating cautious investor sentiment regarding future monetary policy, while closely monitoring upcoming corporate earnings and economic data releases.
See More
Henry Schein Reports Record Q4 Sales Growth and Leadership Transition
- Leadership Transition: Henry Schein announced Fred Lowery will take over as CEO next week, bringing 20 years of experience from Thermo Fisher Scientific, where he successfully scaled businesses through acquisitions and organic growth, which is expected to inject new strategic momentum into the company.
- Significant Sales Growth: The company reported $3.4 billion in sales for Q4, a 7.7% increase year-over-year, marking the highest sales growth in 15 quarters, reflecting the effective execution of the 2025 to 2027 BOLD+1 strategic plan and enhancing future market competitiveness.
- Optimistic Earnings Outlook: For 2026, sales growth is projected to be between 3% and 5%, with non-GAAP EPS expected to range from $5.23 to $5.37, indicating a 5% to 8% increase compared to 2025, showcasing the company's confidence in its future profitability.
- Innovation and Expansion: The company has made strides in e-commerce, product innovation, and new partnerships, including an AI integration partnership with Amazon Web Services, further solidifying its market position in high-growth, high-margin businesses.
See More
Henry Schein Exceeds Q4 Earnings Estimates, Guides Steady 2026 Growth
- Earnings Beat: Henry Schein's Q4 earnings and sales surpassed market expectations, resulting in nearly a 10% share price increase on Tuesday, indicating strong performance and market confidence in the healthcare products sector.
- Sales Growth Drivers: The reported sales growth reflects ongoing demand in the healthcare industry, which is expected to lay a solid foundation for future financial performance and enhance investor confidence in the company's long-term growth potential.
- 2026 Growth Guidance: The company maintains steady growth guidance for 2026, signaling optimism about future market conditions and aiming for sustainable development through continuous innovation and market expansion.
- Increased Shareholder Returns: With the significant rise in share price, the company may consider enhancing shareholder return measures, further attracting investors and increasing market attention on its stock.
See More
Analysis of Stock Price Movements for Multiple Companies
- Dillard's Revenue Decline: Dillard's reported fourth-quarter revenue of $1.99 billion, falling short of the $2.03 billion expected by analysts, leading to a 7% drop in shares, primarily due to winter storms impacting over a third of its stores, highlighting the significant effect of seasonal weather on retail performance.
- Planet Fitness Weak Guidance: Planet Fitness anticipates full-year adjusted earnings per share growth of only 9% to 10%, well below the 16.5% expected by analysts, resulting in an 8% decline in shares, reflecting market concerns over its future growth potential.
- Novo Nordisk Price Reduction Strategy: Novo Nordisk announced it would cut monthly list prices for Wegovy and Ozempic by up to 50%, causing a 2% drop in shares, which may impact its market share and profit margins amid increasing competition.
- Vir Biotechnology Stock Surge: Vir Biotechnology's shares surged nearly 30% following positive Phase 1 results for its VIR-5500 treatment for metastatic prostate cancer, indicating strong potential for its research and an increase in market confidence.
See More
Henry Schein Insider Plans to Sell 3.61 Million Shares of Common Stock via Form 144
Stock Sale Announcement: Stanley M. Bergman intends to sell 43,812 shares of Henry Schein (HSIC.US) common stock on March 2, with a total market value of approximately $3.61 million.
Reduction in Shareholding: Stanley M. Bergman has reduced his shareholding in Henry Schein by 53,831 shares since February 26, 2026, with a total value of approximately $4.36 million.
See More
Henry Schein Reports Strong Q4 Earnings Exceeding Expectations
- Earnings Growth: Henry Schein reported adjusted Q4 earnings of $1.34 per share, a 12.6% increase from $1.19 a year ago, surpassing the consensus estimate of $1.30, indicating sustained profitability improvements.
- Sales Surge: The company achieved Q4 sales of $3.44 billion, exceeding the expected $3.35 billion, reflecting strong performance across global equipment, specialty products, and technology sectors, driving the highest sales growth in 15 quarters.
- Future Guidance: Henry Schein anticipates adjusted earnings for fiscal 2026 to range between $5.23 and $5.37 per share, slightly below the consensus of $5.30, while projecting sales of $13.58 billion to $13.84 billion, indicating a year-over-year growth of 3% to 5%, showcasing confidence in future performance.
- Stock Fluctuation: Despite strong earnings, Henry Schein's stock fell 1.7% to $81.90 on Wednesday, reflecting market caution regarding the company's future performance, which may impact investor sentiment.
See More
US Stocks Rebound Led by Software and Chipmakers
- Market Rebound: The S&P 500 Index rose by 0.77%, the Dow Jones Industrial Average increased by 0.76%, and the Nasdaq 100 Index climbed by 1.09%, indicating a recovery after Monday's sharp declines, reflecting investor optimism regarding economic data.
- Software and Chip Stocks Surge: Following AI startup Anthropic PBC's emphasis on partnerships, software and chip manufacturers saw significant stock price increases, indicating growing market confidence in the integration of AI technologies, which could enhance their competitive positioning.
- Consumer Confidence Boost: The US February consumer confidence index rose by 2.2 to 91.2, surpassing expectations of 87.1, suggesting increased consumer optimism about the economic outlook, which may lead to higher consumer spending and positively impact economic growth.
- Interest Rates and Economic Data Focus: The market is discounting only a 2% chance of a rate cut at the Fed's March 17-18 meeting, indicating cautious investor sentiment regarding future monetary policy, while closely monitoring upcoming corporate earnings and economic data releases.
See More
Henry Schein Reports Record Q4 Sales Growth and Leadership Transition
- Leadership Transition: Henry Schein announced Fred Lowery will take over as CEO next week, bringing 20 years of experience from Thermo Fisher Scientific, where he successfully scaled businesses through acquisitions and organic growth, which is expected to inject new strategic momentum into the company.
- Significant Sales Growth: The company reported $3.4 billion in sales for Q4, a 7.7% increase year-over-year, marking the highest sales growth in 15 quarters, reflecting the effective execution of the 2025 to 2027 BOLD+1 strategic plan and enhancing future market competitiveness.
- Optimistic Earnings Outlook: For 2026, sales growth is projected to be between 3% and 5%, with non-GAAP EPS expected to range from $5.23 to $5.37, indicating a 5% to 8% increase compared to 2025, showcasing the company's confidence in its future profitability.
- Innovation and Expansion: The company has made strides in e-commerce, product innovation, and new partnerships, including an AI integration partnership with Amazon Web Services, further solidifying its market position in high-growth, high-margin businesses.
See More
Henry Schein Exceeds Q4 Earnings Estimates, Guides Steady 2026 Growth
- Earnings Beat: Henry Schein's Q4 earnings and sales surpassed market expectations, resulting in nearly a 10% share price increase on Tuesday, indicating strong performance and market confidence in the healthcare products sector.
- Sales Growth Drivers: The reported sales growth reflects ongoing demand in the healthcare industry, which is expected to lay a solid foundation for future financial performance and enhance investor confidence in the company's long-term growth potential.
- 2026 Growth Guidance: The company maintains steady growth guidance for 2026, signaling optimism about future market conditions and aiming for sustainable development through continuous innovation and market expansion.
- Increased Shareholder Returns: With the significant rise in share price, the company may consider enhancing shareholder return measures, further attracting investors and increasing market attention on its stock.
See More
Analysis of Stock Price Movements for Multiple Companies
- Dillard's Revenue Decline: Dillard's reported fourth-quarter revenue of $1.99 billion, falling short of the $2.03 billion expected by analysts, leading to a 7% drop in shares, primarily due to winter storms impacting over a third of its stores, highlighting the significant effect of seasonal weather on retail performance.
- Planet Fitness Weak Guidance: Planet Fitness anticipates full-year adjusted earnings per share growth of only 9% to 10%, well below the 16.5% expected by analysts, resulting in an 8% decline in shares, reflecting market concerns over its future growth potential.
- Novo Nordisk Price Reduction Strategy: Novo Nordisk announced it would cut monthly list prices for Wegovy and Ozempic by up to 50%, causing a 2% drop in shares, which may impact its market share and profit margins amid increasing competition.
- Vir Biotechnology Stock Surge: Vir Biotechnology's shares surged nearly 30% following positive Phase 1 results for its VIR-5500 treatment for metastatic prostate cancer, indicating strong potential for its research and an increase in market confidence.
See More
